secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2022-05-31T23:59:59+00:00
Accession:  0000950170-22-010890
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon reports positive Phase 2a topline results for tegoprubart in ALS patients
--------------------------------------------------------------------------------

- Tegoprubart met primary safety and tolerability endpoints; no drug-related serious adverse events observed.
- Dose-dependent target engagement at 4 and 8 mg/kg; anti-drug antibodies in <5% of samples, low titer.
- Pro-inflammatory ALS signature of 32 biomarkers identified; dose-dependent reduction in up to 23 biomarkers.
- Trend in slowing ALS progression (ALSFRS slope) vs. PRO-ACT database; study not powered for efficacy.
- Reduced biomarkers also associated with IgA nephropathy and kidney transplant rejection (IgA, C3, CXCL9, etc.).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000095017022010890/0000950170-22-010890-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000095017022010890/eldn-20220531.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-010890

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer